3C
BIVV

361 Capital’s Bioverativ Inc. Common Stock BIVV Stock Holding History

361 Capital’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29,741
Closed -$1.6M – 382
2017
Q4 		$1.6M Buy
29,741
+2,524
+9% +$138K 0.4% 131
2017
Q3 		$1.55M Buy
+27,217
New +$1.59M 0.3% 168

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

361 Capital's BIVV Position: Q1 2018 in Review

361 Capital sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 29,741 shares — an estimated $1.6M sold.

361 Capital first reported a position in BIVV in Q3 2017 and held it in 2 quarters. The position peaked at $1.6M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • 361 Capital reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • 361 Capital sold 29,741 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $1.6M.
  • 361 Capital first reported a position in Bioverativ Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • 361 Capital's Bioverativ Inc. Common Stock position peaked at $1.6M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on 361 Capital's 13F filing for Q1 2018, filed 15 May 2018.